BioCurex Inc.'s RECAF(TM) Blood Test for Cancer Can Prevent Two Thirds of Unnecessary Prostate Biopsies

September 8, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

RICHMOND, British Columbia, Sept. 8, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.

Twitter
LinkedIn
Facebook
Email
Print